Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692

Journal of Nuclear Medicine

Volumn 47, Issue 9, 2006, Pages 1434-1439

  Bach Gansmo, Tore ^a   Danielsson, Rimma ^b   Saracco, Ariel ^b   Wilczek, Brigitte ^b   Bogsrud, Trond V ^a   Fangberget, Anne ^a   Tangerud, Åse ^c   Tobin, Derek ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d GE HEALTHCARE   (Norway)

Author keywords

99mTc labeled peptide; Angiogenesis; Breast cancer; Clinical trial; Integrin

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; NC 100692; NC 100692 TC 99 M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; CYCLOPEPTIDE; DIAGNOSTIC AGENT; TECHNETIUM 99M NC 100692; TECHNETIUM COMPLEX; TUMOR MARKER; TUMOR PROTEIN; VITRONECTIN RECEPTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; ECHOGRAPHY; ELECTROCARDIOGRAM; ENDOTHELIUM CELL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAMMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UPREGULATION; VITAL SIGN; AGED; BREAST TUMOR; EVALUATION; FEASIBILITY STUDY; FEMALE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PILOT STUDY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VASCULARIZATION;

ADULT; AGED; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; PILOT PROJECTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33750598987     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brooks PC, Clark RA, Cheresh DA. Requirements of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
2. LineBR, Mitra A, Nan A, Ghandehari H. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med. 2005;46:1552-1560.
3. Conforti G, Dominguez-Jimenez C, Zanetti A, et al. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood. 1992;80:437-446.
4. Felmeden DC, Blann AD, Lip GYH. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J. 2003;92:400-405.
5. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol. 2003;13:159-167.
6. 3 integrin "vitronectin receptor". Int J Biochem Cell Biol. 1997;29:721-725.
7. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphavbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4:623-626.
8. Mitra A, Mulholland J, Nan A, McNeil E, Ghandehari H, Line BR. Targeting tumor angiogenic vasculature using polymer RGD conjugates. J Controlled Release. 2005;102:191-201.
9. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alphavbeta3 integrin binding peptides in nude mouse model. Cancer Res. 2002;62:6146-6151.
10. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD containing peptides: tracers for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
11. Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;290:H232-H239.
12. 99mTc-labeled peptide targeted at avb3 integrin after murine hindlimb ischemia. Circulation. 2005;111:3255-3260.
13. Kahlkhali I, Mena I, Jouanne E, at al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994;178:491-497.
14. 99mTc-MIBI identify multifocal and multcentric primary breast cancer? Nucl Med Commun. 2001;22:1287-1293.
15. 99mTc sestamibi uptake and histological malignancy grade in invasive breast carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:662-666.
16. Liberman M, Sampalis F, Mulder DS, Sampalis JS. Breast cancer diagnosis by scintimammography: a metaanalysis and review of the literature. Breast Cancer Res Treat. 2003;80:115-126.
17. 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med. 2000;41:1973-1979.
18. Buscombe JR, Cwikla JB, Holloway B, Wilson A. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med. 2001;42:3-8.
19. Schillaci O, Buscome JR. Breast scintigraphy today. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S35-S45.
20. Waxman A, Nagarj N, Kovalevsky M, et al. Detection of primary breast malignancy with Tc99m-MIBI in patients with non-palpable primary malignancies: the importance of lesion size [abstract]. J Nucl Med. 1995;36(suppl):194P.
21. Haubner R, Weber BA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and 18 Galacto-RGD. PLoS Med. March 29, 2005 [Epub ahead of print].
22. 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res. 2006;26:431-434.
23. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.